Patients
Because everyone deserves to live a full life.
We’re passionate about developing therapies to slow or even halt declining brain function. That’s why we are working tirelessly so that people living with, or at risk for, neurodegenerative diseases have a more hopeful future.
Frontotemporal Dementia (FTD)
Frontotemporal dementia (FTD) is the most common dementia in individuals under 60. FTD affects approximately 50,000 to 60,000 individuals in the United States and roughly 110,000 individuals in the United Kingdom and European Union. We are developing treatments that slow the progression of FTD caused by a GRN gene mutation (FTD-GRN).
Alzheimer’s Disease
Alzheimer’s disease is an irreversible degenerative brain disease and the most common form of dementia. It slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. We are advancing therapies for Alzheimer’s disease with the goal of preserving brain function and potentially slowing or even halting the course of disease progression.
Compassionate Use / Expanded Access Programs
Alector is committed to developing safe and effective therapies to transform the lives of patients with neurodegenerative diseases.
